Prevalence of germline truncating mutations in ATM in women with a second breast cancer after radiation therapy for a contralateral tumor - PubMed (original) (raw)

S Levitz, A J Nixon, L A Gibans, K E Nichols, D W Bell, C Ishioka, K J Isselbacher, R Gelman, J Garber, J R Harris, D A Haber

Affiliations

PMID: 10612799

Prevalence of germline truncating mutations in ATM in women with a second breast cancer after radiation therapy for a contralateral tumor

T D Shafman et al. Genes Chromosomes Cancer. 2000 Feb.

Abstract

Patients treated with conservative surgery and radiation therapy for early-stage breast cancer develop a contralateral breast cancer at a rate of approximately 0.75% per year. Ataxia-telangiectasia (AT) is an autosomal recessive disease that is characterized by increased sensitivity to ionizing radiation (IR) and cancer susceptibility. Epidemiologic studies have suggested that AT carriers, who comprise 1% of the population, may be at an increased risk for developing breast cancer, particularly after exposure to IR. To test this hypothesis, we analyzed blood samples from 57 patients who developed a contralateral breast cancer at least 6 months after completion of radiation therapy for an initial breast tumor. A cDNA-based truncation assay in yeast was used to test for heterozygous mutations in the ATM gene, which is responsible for AT. No mutations were detected. Our findings fail to support the hypothesis that AT carriers account for a significant fraction of breast cancer cases arising in women after exposure to radiation. Genes Chromosomes Cancer 27:124-129, 2000.

PubMed Disclaimer

Cited by

Cancer risks attributable to low doses of ionizing radiation: assessing what we really know.
Brenner DJ, Doll R, Goodhead DT, Hall EJ, Land CE, Little JB, Lubin JH, Preston DL, Preston RJ, Puskin JS, Ron E, Sachs RK, Samet JM, Setlow RB, Zaider M. Brenner DJ, et al. Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):13761-6. doi: 10.1073/pnas.2235592100. Epub 2003 Nov 10. Proc Natl Acad Sci U S A. 2003. PMID: 14610281 Free PMC article.
The Breast Cancer Tumor Suppressor TRIM29 Is Expressed via ATM-dependent Signaling in Response to Hypoxia.
Dükel M, Streitfeld WS, Tang TC, Backman LR, Ai L, May WS, Brown KD. Dükel M, et al. J Biol Chem. 2016 Oct 7;291(41):21541-21552. doi: 10.1074/jbc.M116.730960. Epub 2016 Aug 17. J Biol Chem. 2016. PMID: 27535224 Free PMC article.
Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility.
de Jong MM, Nolte IM, te Meerman GJ, van der Graaf WT, Oosterwijk JC, Kleibeuker JH, Schaapveld M, de Vries EG. de Jong MM, et al. J Med Genet. 2002 Apr;39(4):225-42. doi: 10.1136/jmg.39.4.225. J Med Genet. 2002. PMID: 11950848 Free PMC article. Review.
Workshop on The Epidemiology of the ATM Gene: Impact on Breast Cancer Risk and Treatment, Present Status and Future Focus, Lillehammer, Norway, 29 June 2002.
Bernstein JL, Seminara D, Børresen-Dale AL. Bernstein JL, et al. Breast Cancer Res. 2002;4(6):249-52. doi: 10.1186/bcr551. Epub 2002 Oct 9. Breast Cancer Res. 2002. PMID: 12473172 Free PMC article.
ATM variants 7271T>G and IVS10-6T>G among women with unilateral and bilateral breast cancer.
Bernstein JL, Bernstein L, Thompson WD, Lynch CF, Malone KE, Teitelbaum SL, Olsen JH, Anton-Culver H, Boice JD, Rosenstein BS, Børresen-Dale AL, Gatti RA, Concannon P, Haile RW; WECARE Study Collaborative Group. Bernstein JL, et al. Br J Cancer. 2003 Oct 20;89(8):1513-6. doi: 10.1038/sj.bjc.6601289. Br J Cancer. 2003. PMID: 14562025 Free PMC article.

Prevalence of germline truncating mutations in ATM in women with a second breast cancer after radiation therapy for a contralateral tumor - PubMed (original) (raw)